Floatz Rating
B60/100
Confidence
Indicative
Sponsor
Henrik Lindman
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06152471CT.gov Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diarrheal Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Salovum (this asset) | Henrik Lindman | P3 | B · 60 |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | University of Southern California | P3 | BB |
| Irinotecan | Roswell Park Cancer Institute | P3 | BB |
| Loperamide | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P3 | BB |
| Crofelemer | Napo Pharmaceuticals, Inc. | P3 | BB |
| Sulfasalazine | Alliance for Clinical Trials in Oncology | P3 | BB |
| L-Ofloxacin | Children's Oncology Group | P3 | BB |
| Elsiglutide | Helsinn Healthcare SA | P2 | B |
| Colesevelam | Memorial Sloan Kettering Cancer Center | P2 | B |
+16 more in the Diarrheal Disease cohort
Other indications for Salovum
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-University of Southern CaliforniaBB
- IrinotecanRoswell Park Cancer InstituteBB
- LoperamideSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityBB
- CrofelemerNapo Pharmaceuticals, Inc.BB
- SulfasalazineAlliance for Clinical Trials in OncologyBB
Citation
Floatz Terminal. Salovum in Diarrheal Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/salovum-diarrheal-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →